Travere Therapeutics sees Q4 total U.S. net product sales $127M

Q4 revenue consensus $142.18M. Travere Therapeutics (TVTX) announced that, based on preliminary and unaudited financial data, the company expects total U.S. net product sales for the fourth quarter of 2025 to be approximately $127M. For the fiscal year 2025, the company expects total U.S. net product sales to be approximately $410M. The company ended 2025 with approximately $323M in cash, cash equivalents, and marketable securities. “The fourth quarter closed out an exceptional year of commercial execution with FILSPARI, as our teams were able to reach a record number of patients with IgAN, reinforcing its role as foundational therapy,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “As we move into 2026, we are focused on sustaining this momentum while preparing for a successful commercial launch of FILSPARI in FSGS, which, if approved, would be the first approved medication for these patients facing potential kidney failure. In addition, we are well-positioned to restart the pivotal Phase 3 HARMONY Study of pegtibatinase in the first quarter now that we have further optimized our manufacturing process. This marks an important next step in advancing our pipeline and delivering the first potentially disease-modifying therapy for people living with classical HCU.”